Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.33 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL636113 | 1.00 | PTGS2 (0.38) | PTGS2PTGS1LMNAMEN1BLM | |
| SCHEMBL398591 | 1.00 | PTGS2 (0.38) | PTGS2PTGS1LMNAMEN1BLM | |
| SCHEMBL13216744 | 0.95 | PTGS1 (0.37) | PTGS2PTGS1LMNAMEN1BLM | |
| SCHEMBL13685896 | 0.90 | PTGS2 (0.39) | PTGS2PTGS1LMNAMEN1BLM | |
| SCHEMBL23927587 | 0.90 | PTGS2 (0.39) | PTGS2PTGS1LMNAMEN1BLM | |
| Citric Acid SCHEMBL21682507 | 0.88 | ALDH1A1 (0.39) | PTGS2PTGS1 | |
| Citric Acid SCHEMBL23924223 | 0.88 | ALDH1A1 (0.39) | PTGS2PTGS1 | |
| SCHEMBL3232094 | 0.88 | PTGS2 (0.35) | PTGS2PTGS1 | |
| SCHEMBL3239231 | 0.88 | PTGS2 (0.35) | PTGS2PTGS1 | |
| SCHEMBL5183160 | 0.83 | PTGS2 (0.35) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121665-B1 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2121664-B1 | DINITRATE DERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-2274279-B1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| EP-2238143-B1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2012-08-15 | — | — | EP | disclosed |
| US-8101658-B2 | Nitric oxide donating prostamides | NICOX S.A. (FR) | 2012-01-24 | — | — | US | disclosed |
| WO-2011101245-A1 | NITRIC OXIDE RELEASING COMPOUNDS FOR THE TREATMENT OF NEUROPATHIC PAIN | NICOX S.A. (FR) | 2011-08-25 | — | — | WO | disclosed |
| US-8003811-B2 | Nitric oxide donor compounds | NICOX S.A. (FR) | 2011-08-23 | — | — | US | disclosed |
| WO-2011092065-A1 | NITRIC OXIDE RELEASING COMPOUNDS FOR THE TREATMENT OF NEUROPHATIC PAIN | NICOX S.A. (FR) | 2011-08-04 | — | — | WO | disclosed |
| EP-2313417-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | Nicox S.A. (FR) | 2011-04-27 | — | — | EP | disclosed |
| US-20110092590-A1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX S.A. (FR) | 2011-04-21 | — | — | US | disclosed |
| US-20100249189-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100152258-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152259-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010015447-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2010-02-11 | — | — | WO | disclosed |
| WO-2009150007-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2009-12-17 | — | — | WO | disclosed |
| EP-2121664-A2 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009136281-A1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX S.A. (FR) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009098113-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2009-08-13 | — | — | WO | disclosed |
| US-20080194660-A1 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| WO-2008076245-A2 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194660-A1 | Angiotensin II receptor antagonists | AGTR1, AGTR2, REN | PTGS2 1456/4885PTGS1 1479/4885LMNA 3849/4885 |
| US-20100249189-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS1, NOS2 | PTGS2 105/4885PTGS1 56/4885LMNA 2520/4885 |
| US-20110092590-A1 | NITRIC OXIDE DONATING PROSTAMIDES | PTGIS, PTGIR, NOS2 | PTGS2 6/4885PTGS1 4/4885LMNA 2573/4885 |
| US-20100152258-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR2, AGTR1, NPY2R | PTGS2 856/4885PTGS1 1015/4885LMNA 4134/4885 |
| US-20100152259-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | PTGS2 1359/4885PTGS1 1397/4885LMNA 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.